{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:10:32Z","timestamp":1653516632193},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":7450,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1999,8]]},"DOI":"10.1023\/a:1008339010655","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"915-921","source":"Crossref","is-referenced-by-count":13,"title":["Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: A phase I study of the Southern Italy Cooperative Oncology Group"],"prefix":"10.1016","volume":"10","author":[{"given":"P.","family":"Comella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Casaretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Orditura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gravina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Faranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Comis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Comella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008339010655_bb0060","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJM197811092991906","article-title":"Chemotherapy of gastrointestinal cancer","volume":"299","author":"Moertel","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1023\/A:1008339010655_bb0065","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1200\/JCO.1992.10.6.896","article-title":"Modulation of fluorouracil by leucovorin in terms of response rate","volume":"10","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008339010655_bb0070","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1126\/science.2555920","article-title":"DNA Topoisomerase I-targeted chemotherapy of human colon cancer in xenografts","volume":"246","author":"Giovannella","year":"1989","journal-title":"Science"},{"key":"10.1023\/A:1008339010655_bb0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/oxfordjournals.annonc.a059109","article-title":"Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase 1 trials","volume":"6","author":"Chabot","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008339010655_bb0080","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1996.14.10.2688","article-title":"Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer","volume":"14","author":"Canal","year":"1996","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1023\/A:1008339010655_bb0085","first-page":"34","article-title":"CPT-11 in the treatment of colorectal cancer: Clinical efficacy and safety profile","volume":"23","author":"Rougier","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008339010655_bb0090","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1023\/A:1008270717294","article-title":"Topoisomerase I inhibitors: Review and update","volume":"8","author":"Rothenberg","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008339010655_bb0095","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.1993.11.5.909","article-title":"Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer","volume":"11","author":"Shimada","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008339010655_bb0100","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.1996.14.4.1128","article-title":"Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer","volume":"14","author":"Rothember","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008339010655_bb0105","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.1996.14.3.709","article-title":"Irinotecan is an active agent in untreated patients with metastatic colorectal cancer","volume":"14","author":"Conti","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008339010655_bb0110","first-page":"284a","article-title":"Phase II study of irinotecan (CPT-11) 250 mg\/m2 given every-other-week in previously treated colorectal cancer patients","volume":"1092","author":"Rothenberg","year":"1998","journal-title":"Proc Thirty-Fourth Meet Am Soc Clin Oncol"},{"key":"10.1023\/A:1008339010655_bb0115","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/0959-8049(95)00212-2","article-title":"CPT-11 (Irinotecan) in the treatment of colorectal cancer","volume":"31A","author":"Armand","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1008339010655_bb0120","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1988","journal-title":"Lancet"},{"key":"10.1023\/A:1008339010655_bb0125","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"key":"10.1023\/A:1008339010655_bb0130","first-page":"266a","article-title":"A phase II multicenter trial of alternating cycles of irinotecan (CPT-11) and 5-FU\/LV in patients with previously untreated metastatic colorectal cancer (CRC)","volume":"944","author":"Rothenberg","year":"1997","journal-title":"Proc Thirty-Third Meet Am Soc Clin Oncol"},{"key":"10.1023\/A:1008339010655_bb0135","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1023\/A:1008478405634","article-title":"A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer","volume":"9","author":"Van Cutsem","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008339010655_bb0140","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.1996.14.11.2959","article-title":"Phase I clinical trial and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors","volume":"14","author":"Saltz","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008339010655_bb0145","first-page":"202a","article-title":"A phase I and pharmacokinetic (PK) study of CPT-11 (C) and 5-FU (F) combination","volume":"710","author":"Benhammouda","year":"1997","journal-title":"Proc Thirty-Third Meet Am Soc Clin Oncol"},{"issue":"8","key":"10.1023\/A:1008339010655_bb0150","first-page":"756: S169","article-title":"Phase I\u2014II study of CPT-11 in combination with LV + 5-FU (\u2018De Gramont\u2019 regimen) every two weeks for the treatment of colorectal cancer (CRC) after 5-FU failur","volume":"33","author":"Rougier","year":"1997","journal-title":"Proc ECCO 9, Eur J Cancer"},{"key":"10.1023\/A:1008339010655_bb0155","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.1999.17.3.907","article-title":"Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer","volume":"17","author":"Vanhoefer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008339010655_bb0160","first-page":"290a","article-title":"Irinotecan in combination with leucovorin and 5-fluorouracil 48 hours continuous infusion: A phase I study with pharmacokinetic, DNA damage and topoisomerase I\/DNA complexes evaluation in chemotherapy-na\u00efve metastatic colorectal cancer patients","volume":"1117","author":"Falcone","year":"1998","journal-title":"Proc Thirty-Fourth Meet Am Soc Clin Oncol"},{"issue":"4","key":"10.1023\/A:1008339010655_bb0165","first-page":"1780, 37","article-title":"A phase I study of CPT-11 plus chronomodulated (chrono) 5-fluorouracil (5-FU) and L-folinic acid (FA) in advanced colorectal cancer (ACC) patient. Proceedings of the 23rd Congress ESMO","volume":"9","author":"Garufi","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008339010655_bb0170","first-page":"1719","article-title":"Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies","volume":"32A","author":"Cornelia","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1008339010655_bb0175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1023\/A:1008339010655_bb0180","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/oxfordjournals.annonc.a059109","article-title":"Population pharmacokinetics and pharmacodinamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials","volume":"6","author":"Chabot","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008339010655_bb0185","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1995.13.1.210","article-title":"Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every three weeks in cancer patients","volume":"13","author":"Abigerges","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008339010655_bb0190","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1996.14.10.2688","article-title":"Pharmakokinetics and pharmakodinamics of irinotecan during a phase II clinical trial in colorectal cancer","volume":"14","author":"Gay","year":"1996","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1023\/A:1008339010655_bb0195","first-page":"634P, 132","article-title":"Schedule-dependent antitumor efficacy of irinotecan (CPT-11) and 5-fluorouracil (5-FU) in nude mice bearing colon tumor xenografts that are resistant to 5-F. Proceedings of the 23rd ESMO Congress","volume":"9","author":"Vanhoefer","year":"1998","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1023\/A:1008339010655_bb0200","first-page":"181P, 38","article-title":"High dose of CPT-11 (500 mg\/m2) as first-line chemotherapy for metastatic colorectal cancer: Preliminary results of a multicentre phase II tria. Proceedings of the 23rd ESMO Congress","volume":"9","author":"Ychou","year":"1998","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419573057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419573057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/10\/8\/915\/19477810\/10-8-915.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T23:33:32Z","timestamp":1582241612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419573057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1999,8]]}},"alternative-id":["S0923753419573057"],"URL":"https:\/\/doi.org\/10.1023\/a:1008339010655","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1999,8]]}}}